12 clinical protocols redefining CRISPR delivery systems in 2026 The global biotechnology sector is witnessing a decisive transition toward non-viral delivery mechanisms as 2026 unfolds, moving away from traditional viral vectors to mitigate long-term immunogenicity risks. Under new mandates from the European Medicines Agency, standardized lipid nanoparticle (LNP) frameworks are being integrated into multi-center trials to ensure uniform dosage across...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
English
French
Spanish
Italiano
Romaian
Portuguese (Brazil)
china